Dominant lethal study in male mice treated with ofloxacin, a new antimicrobial drug

Cytogenetic alterations in human lymphocyte cultures following exposure to ofloxacin

Ofloxacin (OFX), a second-generation of quinolones, is a broad-spectrum flouroquinolone antibiotic used in the treatment of various bacterial infections. In this article, we aimed to investigate the cytotoxic and genotoxic potentials of OFX in cultured human peripheral lymphocytes. The cytotoxicity and genotoxicity of OFX on human peripheral blood lymphocytes were examined in vitro by sister chromatid exchange (SCE), chromosomal aberrations (CAs) and micronucleus (MN) tests. Cultures were treated with 30, 60 and 120 μg/ml of OFX for 48 h. Dimethylsulfoxide (DMSO) was used as a solvent control. OFX decreased the mitotic index (MI) and nuclear division index (NDI) significantly, especially at higher concentrations (60 and 120 μg/ml) compared with solvent control. OFX significantly induced CAs at all concentrations and SCEs at higher concentrations (60 and 120 μg/ml) compared with solvent control. In conclusion, our results indicated that OFX has cytotoxic, cytostatic and genotoxic potential especially at higher concentrations on human peripheral blood lymphocyte cultures under the experimental conditions.

Ofloxacin: the next generation of antibiotic in sperm and embryo cultures for assisted reproductive technologies

OBJECTIVE

To analyze the effect of different concentrations of ofloxacin on sperm kinematic parameters and to determine the embryotoxicity of ofloxacin at physiologic and at 100x concentrations.

DESIGN

Prospective comparative study.

SETTING

Clinical and academic research environment.

PATIENT(S)

Pooled cryopreserved donor sperm (n = 7).

INTERVENTION(S)

Human sperm were processed through two-layer discontinuous Percoll gradients, and the resultant pellet was resuspended in either HEPES-buffered human tubal fluid medium containing different concentrations of ofloxacin or the control medium. After measuring the kinematic parameters, the percentages of apoptosis and viability were obtained. Next, the sperm DNA was extracted and polymerase chain reaction of beta-globin gene was performed followed by denaturing gradient gel electrophoresis. Mouse embryos recovered at the one-cell pronuclear or zygote stages were cultured in the presence or absence of ofloxacin up to the hatched blastocyst stage and differences in development were recorded.

MAIN OUTCOME MEASURE(S)

Sperm kinematic parameters, sperm beta-globin gene, and number of embryos reaching the hatched blastocyst stage.

RESULT(S)

The number of embryos exposed to control and physiologic ofloxacin concentrations showed comparable excellent growth. However, the 100x concentration significantly arrested development. Rates of sperm viability and apoptosis measured 48 hours after exposure to the above concentrations were not different from controls. No differences were noted in the sperm kinematic parameters of sperm exposed to ofloxacin concentrations (1x, 10x, and 100x) or control medium after 0, 4, and 48 hours of incubation. Denaturing gradient gel electrophoresis of beta-globin genes from DNA exposed to varying ofloxacin concentrations failed to show any point mutations.

CONCLUSION(S)

Ofloxacin was embryotoxic at pharmacologic concentrations (100x). At physiologic or higher concentrations, ofloxacin appears to be safe and does not affect sperm kinematic parameters when compared with controls. This may indicate that sperm motility parameters alone cannot be relied on to evaluate the effects of drugs on fertility and that in vitro embryologic studies are essential. Ofloxacin at any concentration did not alter the rates of sperm apoptosis or viability. Ofloxacin does not appear to be mutagenic as evidenced by the beta-globin gene analysis.

Antibiotics: effect on cryopreserved-thawed human sperm motility in vitro

OBJECTIVE

To analyze the motility and fertilizing capacity of sperm treated with different antibiotics.

DESIGN

Prospective comparative study.

SETTING

Clinical and academic research environment.

PATIENT(S)

Pooled cryopreserved donor sperm (n = 14).

INTERVENTION(S)

Sperm were washed with Percoll and resuspended in HEPES-buffered human tubal fluid medium containing either amoxicillin, ofloxacin, ciprofloxacin hydrochloride, nitrofurantoin monohydrate, doxycycline hyclate, cefuroxime axetil, or control medium.

MAIN OUTCOME MEASURE(S)

Sperm kinematic and fertilizing parameters.

RESULT(S)

Sperm hyperactivation was decreased in physiologic concentrations of ciprofloxacin hydrochloride and doxycycline hyclate over the course of 48 hours. At pharmacologic concentrations, ciprofloxacin hydrochloride, cefuroxime axetil, and nitrofurantoin monohydrate adversely affected motility with decreased rapid progression. Cessation of motility occurred in cefuroxime axetil and nitrofurantoin monohydrate. Sperm hyperactivation was also absent. Cefuroxime axetil decreased the percentage of intact acrosomes. In contrast, physiologic doses of ciprofloxacin hydrochloride or ofloxacin enhanced sperm fertilizing capacity.

CONCLUSION(S)

Ciprofloxacin affected hyperactivation by altering membrane properties, whereas doxycycline inhibited the capacitation process. Cessation of motility in cefuroxime axetil was linked to disrupted sperm head membranes. Sperm motility and fertilizing capacity were decreased in nitrofurantoin because of decreased metabolism. The positive effect of ofloxacin on fertilizing capacity did not involve changes in acrosome.

Toxicity of quinolone antimicrobial agents

An approach to minimization of toxicity of a new compound is to elucidate the mechanisms of toxicity of analogous compounds and to clarify their structure-toxicity relationships. A problem with this approach, however, is that such elucidation remains difficult. For quinolones, some improvements in this mechanistic approach have been achieved in the central nervous system (CNS), particularly with regard to their interaction with non-steroidal anti-inflammatory drugs (NSAIDs), and in genotoxicity and phototoxicity studies, particularly in comparison with other toxicities, such as to the cardiovascular, gastrointestinal, bone, reproductive, and developmental systems. This review concentrates on a description of the known effects of quinolones on various organ systems in experimental animals and humans. Given the logarithmic increase in the synthesis of new quinolones, it is questionable whether these drugs share similar safety and efficacy. Nevertheless, this mechanistic approach to the investigation and minimization of toxicity has produced satisfactory results to date and deserves to be continued.

Comparison of organ-specific toxicity of temafloxacin in animals and humans

This article summarizes animal studies conducted to determine the toxic and mutagenic potential of temafloxacin. The four target tissues of potential concern with fluoroquinolone use are the kidney, the eye, the weight-bearing joints of young animals, and the central nervous system. Based on the results of these studies in rats and dogs, it appears unlikely that crystalluria or nephrotoxicity will occur in humans who receive temafloxacin. Pre-marketing clinical trials in humans (n = 5,308) correlate well with chronic toxicity animal studies, reporting no crystalluria or clinically significant nephrotoxicity. Reversible electroretinographic (ERG) changes in dog studies were demonstrated only with the administration of high temafloxacin dosages. A Phase I study evaluating the safety of temafloxacin at 600 mg b.i.d. for 14 days in human subjects reported no significant changes in ophthalmologic parameters. Evidence of cartilaginous joint damage was observed in puppies receiving oral temafloxacin, in young dogs receiving intravenous temafloxacin, and in a single dog receiving a lethal dosage in a dose range-finding study. However, these toxic findings were not evident in any dogs in the subacute or chronic oral toxicity studies or in a longer duration intravenous study. Although limited evidence would suggest that young children may not be at risk, thorough clinical investigations of quinolones in these patients have only recently been initiated. Signs of central nervous system toxicity caused by temafloxacin were absent in two rodent studies, during which clonic convulsions were induced by concomitant use of fenbufen plus enoxacin or ciprofloxacin, and in human subjects evaluated by positron emission tomography. Temafloxacin, contrary to most other quinolones, was considered nonmutagenic in all mutagenicity tests conducted. In reproductive studies, temafloxacin was not uniquely toxic to the developing conceptus in the laboratory rat, mouse, rabbit, or primate. Based on these animal studies, temafloxacin appears to be non-mutagenic and to have a low potential for producing renal or ocular toxicity; however, like other quinolones, it should not be routinely used in children or pregnant women because of evidence of cartilage damage reported in young dogs. Premarketing clinical trials to date confirm the safety of temafloxacin use in adults.

Antibiotics: potential hazards to male fertility

Individual agents within each of the major classes of antibiotics have been shown to have significant adverse effects on spermatogenesis or spermatozoal function in mammals. For humans, infertility or significant alterations in semen parameters have been well documented for the nitrofurans and for patients on sulfasalazine. Other commonly used antibiotics, such as minocycline, have been shown to be toxic to sperm at any concentration. Until further information is available, clinicians must keep in mind that treatment with antibiotics may adversely affect the fertility potential of men. It is possible that some classes of antibiotic agents, such as the penicillins or the quinolones, may have minimal effects on male fertility and maintain the clinical efficacy for patients requiring long-term antibiotic suppressive therapy. Further investigation is needed into the relative toxicity of antibiotics and the mechanisms by which antibiotics affect spermatogenesis and spermatozoal function. A background of the current state of knowledge regarding the adverse effects of antibiotics on male fertility is presented in this review.

Fluoroquinolone antimicrobial agents

The fluoroquinolones, a new class of potent orally absorbed antimicrobial agents, are reviewed, considering structure, mechanisms of action and resistance, spectrum, variables affecting activity in vitro, pharmacokinetic properties, clinical efficacy, emergence of resistance, and tolerability. The primary bacterial target is the enzyme deoxyribonucleic acid gyrase. Bacterial resistance occurs by chromosomal mutations altering deoxyribonucleic acid gyrase and decreasing drug permeation. The drugs are bactericidal and potent in vitro against members of the family Enterobacteriaceae, Haemophilus spp., and Neisseria spp., have good activity against Pseudomonas aeruginosa and staphylococci, and (with several exceptions) are less potent against streptococci and have fair to poor activity against anaerobic species. Potency in vitro decreases in the presence of low pH, magnesium ions, or urine but is little affected by different media, increased inoculum, or serum. The effects of the drugs in combination with a beta-lactam or aminoglycoside are often additive, occasionally synergistic, and rarely antagonistic. The agents are orally absorbed, require at most twice-daily dosing, and achieve high concentrations in urine, feces, and kidney and good concentrations in lung, bone, prostate, and other tissues. The drugs are efficacious in treatment of a variety of bacterial infections, including uncomplicated and complicated urinary tract infections, bacterial gastroenteritis, and gonorrhea, and show promise for therapy of prostatitis, respiratory tract infections, osteomyelitis, and cutaneous infections, particularly when caused by aerobic gram-negative bacilli. Fluoroquinolones have also proved to be efficacious for prophylaxis against travelers' diarrhea and infection with gram-negative bacilli in neutropenic patients. The drugs are effective in eliminating carriage of Neisseria meningitidis. Patient tolerability appears acceptable, with gastrointestinal or central nervous system toxicities occurring most commonly, but only rarely necessitating discontinuance of therapy. In 17 of 18 prospective, randomized, double-blind comparisons with another agent or placebo, fluoroquinolones were tolerated as well as or better than the comparison regimen. Bacterial resistance has been uncommonly documented but occurs, most notably with P. aeruginosa and Staphylococcus aureus and occasionally other species for which the therapeutic ratio is less favorable. Fluoroquinolones offer an efficacious, well-tolerated, and cost-effective alternative to parenteral therapies of selected infections.

Ofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use

Ofloxacin is one of a new generation of fluorinated quinolones structurally related to nalidixic acid. It is an orally administered broad spectrum antibacterial drug active against most Gram-negative bacteria, many Gram-positive bacteria and some anaerobes. Ciprofloxacin is the only other quinolone with superior in vitro antibacterial activity. However, the pharmacokinetic profile of ofloxacin is superior to that of ciprofloxacin, with more rapid absorption and a peak serum concentration several times higher. Moreover, ofloxacin achieves high concentrations in most tissues and body fluids. The results of clinical trials with ofloxacin have confirmed the potential for use in a wide range of infections, which was indicated by its in vitro antibacterial and pharmacokinetic profiles. It has proven effective against a high percentage of infections caused by Gram-negative organisms, slightly less effective against Gram-positive infections, and effective against some anaerobic infections. Clinical efficacy has also been confirmed in a variety of systemic infections as well as in acute and chronic urinary tract infections, and ofloxacin has generally appeared to be at least as effective as alternative orally administered antibacterial drugs. Ofloxacin is well tolerated and, although experience with the drug in clinical practice to date is limited, bacterial resistance does not appear to develop readily. Thus, ofloxacin is an orally active drug which offers a valuable alternative to other broad spectrum antibacterial drugs.

[No indications for the mutagenicity of ofloxacin]

The antibacterial activity of ofloxacin, as demonstrated in the Rec assay, showed a harmful effect on the DNA of Bacteroides subtilis. In contrast, there was no significant harmful effect on the DNA of eukaryonts. Ofloxacin did not cause any point mutations, nor did it induce any in vivo or in vitro chromosome mutation in the systems tested. These tests lead us to the conclusion that there are no indications of ofloxacin having any mutagenic effects.